### **CONSULTATION PROFORMA**

#### **ATTACHMENT A**

### MARKET INDEX DEFINITION STATEMENT (MIDS) CONSULTATION PROFORMA

We are seeking your views on the MIDS review. If you represent BSC Parties or any other party in connection with the MIDS your responses to the consultation should be submitted in this proforma.

Please send your responses to market.operations@elexon.co.uk by Thursday 3 October 2019 and use email subject 'MIDS Review 2019'.

Respondent:	Name		
Company Name:			
No. of BSC Parties			
Represented			
Parties Represented	Please list all BSC Party names of Parties responding on behalf of (including the respondent company if relevant).		
No. of Non BSC Parties			
Represented (e.g. Agents)			
Non Parties represented	Please list all non Parties responding on behalf of (including the respondent company if relevant).		
Role of Respondent	(Supplier/Generator/ Trader / Consolidator / Exemptable Generator / BSC Agent / Party Agent / Distributors / other – please state 1)		
Can we publish your response on the ELEXON website?			



<sup>&</sup>lt;sup>1</sup> Delete as appropriate – please do not use strikeout, this is to make it easier to analyse the responses

# **CONSULTATION PROFORMA**

Q	Question	Yes/No 1	Rationale
1	BSC Modification P377, implemented in April 2019, changed the timeband descriptions in the Market Index Definition Statement to refer to the Submission Deadline, and also removed timeband 6 as a weighted timeband.  ELEXON propose not to review the current weighted timebands until a full year's worth of Market Index Data is available following the implementation of P377.  Do you agree with this proposal? Please give your rationale.	Yes / No	
2	The Individual Liquidity Threshold should remain at 25 MWh.  Do you agree with this? Please give your rationale.	Yes / No	
3	Currently products H, 1, 2 and 4 are weighted '1' meaning only these products are included in the calculation of Market Index Price.  Do you agree with the current product weightings? Please give your rationale.	Yes / No	



# **CONSULTATION PROFORMA**

4	Do you have any further comments regarding this MIDS review?		

